Compare Petróleo Brasileiro SA (PBR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Sana Biotechnology Inc — how do they compare? Petróleo Brasileiro SA trades at $25.27 (market cap $151.94B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Petróleo Brasileiro SA is far larger — about 181.6× Sana Biotechnology Inc's market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 25 Days and Sana Biotechnology Inc for 23 Days on average.
| PBR | SANA | |
|---|---|---|
Market Cap | $151.94B | $836.71M |
Volume | 30,240,092 | 4,507,444 |
Sector | Energy | Health |
52-Week High | $24.69 | $5.92 |
52-Week Low | $11.54 | $2.68 |
Typical Hold Time | 25 Days | 23 Days |
Enterprise Value | $212.36B | $749.96M |
Dividend Yield | 6.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) is trading at $25.16, up 4.88% with strong bullish momentum. The stock shows robust fundamentals with a P/E of 6.24, net margin of 24.52%, and positive earnings surprises in recent quarters. Recent news highlights new oil discoveries and production growth initiatives, while technical indicators show overbought conditions with RSI above 80.
PBR offers attractive valuation metrics and strong profitability, but faces risks from political interference and commodity price volatility. Analyst consensus leans bullish with 50% buy ratings, though the current price exceeds the $22.33 consensus target. The company's expansion projects and LNG deals provide long-term growth catalysts.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
